UConn Technology Incubation Program (TIP) startup, CaroGen, recently announced the publication of research relating to their proprietary therapeutic Hepatitis B vaccine technology. According to the company’s CEO, Dr. Bijan Almassian, “the publication of this work [in the August online issue of the Journal of Virology] is a major milestone for CaroGen, as it provides a peer-reviewed report of our proof-of-concept HBV vaccine studies to date.” Click to read the full publication.
CaroGen Corporation is an emerging vaccine company employing a virus-like vesicle (VLV) platform technology developed at Yale University School of Medicine, which is exclusively licensed for the development and commercialization of vaccines worldwide. The company, a member of TIP since December 2014, is developing a portfolio of vaccine candidates with a lead vaccine program in chronic HBV infection – a pathogen of global concern and a leading cause of liver disease and cancer. To visit the company’s website, go to www.carogencorp.com.
To read the full story, visit the Office of the Vice President for Research (OVPR) news page.
For more information, contact: Jessica McBride at jessica.mcbride@uconn.edu